This report provides a quantitative analysis of the current trends, estimations, and dynamics from 2016 to 2023 to assist to identify the prevailing market opportunities.
Portland, OR -- (SBWIRE) -- 09/18/2017 -- Cyclosporine is an immunosuppressant medicine and natural product administered via injection and mouth into veins for the treatment of rheumatoid psoriasis, arthritis, nephrotic syndrome, Crohn's disease, and in organ transplants to prevent rejection. In addition, it is used as eye drops for dry eyes. Ciclosporin was extracted from the fungus Tolypocladium inflatum, and was eventually used for medicinal purposes.
Access to the full summary: https://www.alliedmarketresearch.com/cyclosporine-market
The global cyclosporine market has witnessed significant growth, owing to its widespread use in the medical industry as an oral medicine to treat inflammation in rheumatoid arthritis and psoriasis. In addition, it is used to prevent rejection of an organ transplant, which fuels its demand, thereby supplementing the market growth. However, health concerns associated with cyclosporine such as kidney problems, high blood pressure, gum diseases tremors, and increased body hair hamper the market growth.
Some of the key players in the global market include:
- Herantis Pharma
- Mimetogen Pharmaceuticals
- Mitotech SA
- Otsuka Pharmaceutical
- Regenerx Biopharmaceuticals Inc.
- Santen Pharmaceutical Co., Ltd.
- UNITED BIOTECH (P) LTD.
Cyclosporine Market Key Segments:
- Oral Liquid
Get sample PDF: https://www.alliedmarketresearch.com/request-toc-and-sample/3824
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South Africa
- Rest of LAMEA